{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:03:22Z","timestamp":1790269402048,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04962-1","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:21:35Z","timestamp":1790266895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: a systematic review and meta-analysis of 72,980 patients"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7782-9680","authenticated-orcid":false,"given":"Iago Zang","family":"Pires","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0839-8272","authenticated-orcid":false,"suffix":"Jr.","given":"Alexandre Yamada","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-5060","authenticated-orcid":false,"given":"Mar\u00edlia Oberto","family":"da Silva Gobbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-2784","authenticated-orcid":false,"given":"Renan Yuji Ura","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5320-3040","authenticated-orcid":false,"given":"Tanize Louize","family":"Milbradt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-8158","authenticated-orcid":false,"given":"Nilson Marquardt","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0791","authenticated-orcid":false,"given":"Gustavo Franco","family":"Carvalhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"4962_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"4962_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"4962_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE et al (2021) Prostate cancer. Nat Rev Dis Primers 7:9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0","journal-title":"Nat Rev Dis Primers"},{"key":"4962_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa1606220","journal-title":"N Engl J Med"},{"key":"4962_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"key":"4962_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86:164\u2013182. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010","journal-title":"Eur Urol"},{"key":"4962_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","volume":"68","author":"C Bosco","year":"2015","unstructured":"Bosco C, Bosnyak Z, Malmberg A et al (2015) Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 68:386\u2013396. https:\/\/doi.org\/10.1016\/j.eururo.2014.11.039","journal-title":"Eur Urol"},{"key":"4962_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.21873\/cdp.10160","volume":"2","author":"Y Miyazawa","year":"2022","unstructured":"Miyazawa Y, Sekine Y, Arai S et al (2022) Changes in renal function of patients with prostate cancer: focus on androgen deprivation therapy. Cancer Diagn Progn 2:686\u2013690. https:\/\/doi.org\/10.21873\/cdp.10160","journal-title":"Cancer Diagn Progn"},{"key":"4962_CR9","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.21873\/anticanres.15252","volume":"41","author":"H Masuda","year":"2021","unstructured":"Masuda H, Fujimoto A, Kanesaka M et al (2021) Renal function improves after the discontinuation of androgen deprivation therapy in Japanese patients with prostate cancer. Anticancer Res 41:4443\u20134446. https:\/\/doi.org\/10.21873\/anticanres.15252","journal-title":"Anticancer Res"},{"key":"4962_CR10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF et al (2023) Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol 209:1082\u20131090. https:\/\/doi.org\/10.1097\/JU.0000000000003452","journal-title":"J Urol"},{"key":"4962_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","volume":"185","author":"S Gillessen","year":"2023","unstructured":"Gillessen S, Bossi A, Davis ID et al (2023) Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer 185:178\u2013215. https:\/\/doi.org\/10.1016\/j.ejca.2023.02.018","journal-title":"Eur J Cancer"},{"key":"4962_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41391-021-00383-8","volume":"24","author":"TJ Daskivich","year":"2021","unstructured":"Daskivich TJ (2021) Androgen deprivation therapy and acute kidney injury in prostate cancer: room for debate? Prostate Cancer Prostatic Dis 24:933\u2013934. https:\/\/doi.org\/10.1038\/s41391-021-00383-8","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4962_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","volume":"74","author":"A Nabid","year":"2018","unstructured":"Nabid A, Carrier N, Martin AG et al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol 74:432\u2013441. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.018","journal-title":"Eur Urol"},{"key":"4962_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"DP Dearnaley","year":"2020","unstructured":"Dearnaley DP, Saltzstein DR, Sylvester JE et al (2020) The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial. Eur Urol 78:184\u2013192. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.001","journal-title":"Eur Urol"},{"key":"4962_CR15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008\u20132012. https:\/\/doi.org\/10.1001\/jama.283.15.2008","journal-title":"JAMA"},{"key":"4962_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4962_CR17","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/ndt\/gfag014","volume":"41","author":"L -Del Vecchio","year":"2026","unstructured":"Del Vecchio L, Cases A, Eisenga MF, Ma\u0142yszko J, Barratt J, Bolignano D (2026) KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP). Nephrol Dial Transpl 41:1554\u20131572. https:\/\/doi.org\/10.1093\/ndt\/gfag014","journal-title":"Nephrol Dial Transpl"},{"key":"4962_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"4962_CR19","unstructured":"GRADEpro, GDT [Internet] (2025) Available from: https:\/\/methods.cochrane.org\/gradeing\/gradepro-gdt"},{"key":"4962_CR20","unstructured":"-R Core Team (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. Available from: https:\/\/www.scirp.org\/reference\/referencespapers?referenceid=3131254"},{"key":"4962_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.eururo.2014.01.026","volume":"66","author":"G Gandaglia","year":"2014","unstructured":"Gandaglia G, Sun M, Hu JC et al (2014) Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol 66:1125\u20131132. https:\/\/doi.org\/10.1016\/j.eururo.2014.01.026","journal-title":"Eur Urol"},{"key":"4962_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41391-021-00415-3","volume":"26","author":"MV Sherer","year":"2023","unstructured":"Sherer MV, Deka R, Salans MA et al (2023) Androgen deprivation therapy and acute kidney injury in patients with prostate cancer undergoing definitive radiotherapy. Prostate Cancer Prostatic Dis 26:276\u2013281. https:\/\/doi.org\/10.1038\/s41391-021-00415-3","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4962_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41391-021-00348-x","volume":"24","author":"CR Cardwell","year":"2021","unstructured":"Cardwell CR, O\u2019Sullivan JM, Jain S et al (2021) Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: a population-based cohort study. Prostate Cancer Prostatic Dis 24:1055\u20131062. https:\/\/doi.org\/10.1038\/s41391-021-00348-x","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4962_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/jama.2013.8638","volume":"310","author":"F Lapi","year":"2013","unstructured":"Lapi F, Azoulay L, Niazi MT et al (2013) Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 310:289. https:\/\/doi.org\/10.1001\/jama.2013.8638","journal-title":"JAMA"},{"key":"4962_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1113\/jphysiol.2002.022756","volume":"543","author":"C Molinari","year":"2002","unstructured":"Molinari C, Battaglia A, Grossini E et al (2002) The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol 543:365\u2013372. https:\/\/doi.org\/10.1113\/jphysiol.2002.022756","journal-title":"J Physiol"},{"key":"4962_CR26","doi-asserted-by":"publisher","first-page":"F377","DOI":"10.1152\/ajprenal.00354.2011","volume":"303","author":"MP Hutchens","year":"2012","unstructured":"Hutchens MP, Fujiyoshi T, Komers R et al (2012) Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo. Am J Physiol Ren Physiol 303:F377\u2013F385. https:\/\/doi.org\/10.1152\/ajprenal.00354.2011","journal-title":"Am J Physiol Ren Physiol"},{"key":"4962_CR27","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1046\/j.1523-1755.2001.0590041498.x","volume":"59","author":"N Kambham","year":"2001","unstructured":"Kambham N, Markowitz GS, Valeri AM et al (2001) Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59:1498\u20131509. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.0590041498.x","journal-title":"Kidney Int"},{"key":"4962_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ et al (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102:39\u201346. https:\/\/doi.org\/10.1093\/jnci\/djp404","journal-title":"J Natl Cancer Inst"},{"key":"4962_CR29","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448\u20134456. https:\/\/doi.org\/10.1200\/JCO.2006.06.2497","journal-title":"J Clin Oncol"},{"key":"4962_CR30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2015.4917","volume":"2","author":"M Sun","year":"2016","unstructured":"Sun M, Choueiri TK, Hamnvik OPR et al (2016) Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy. JAMA Oncol 2:500\u2013507. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4917","journal-title":"JAMA Oncol"},{"key":"4962_CR31","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.3747\/co.23.2953","volume":"23","author":"MD Krahn","year":"2016","unstructured":"Krahn MD, Bremner KE, Luo J et al (2016) Long-term health care costs for prostate cancer patients on androgen deprivation therapy. Curr Oncol 23:e443\u2013e453. https:\/\/doi.org\/10.3747\/co.23.2953","journal-title":"Curr Oncol"},{"key":"4962_CR32","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E et al (2018) The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 16:e645\u2013e653. https:\/\/doi.org\/10.1016\/j.clgc.2017.12.007","journal-title":"Clin Genitourin Cancer"},{"key":"4962_CR33","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","volume":"10","author":"O El-Taji","year":"2024","unstructured":"El-Taji O, Taktak S, Jones C et al (2024) Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis. JAMA Oncol 10:874\u2013884. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1549","journal-title":"JAMA Oncol"},{"key":"4962_CR34","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bcp.14972","volume":"88","author":"LM Scailteux","year":"2022","unstructured":"Scailteux LM, Despas F, Balusson F et al (2022) Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients. Br J Clin Pharmacol 88:336\u2013346. https:\/\/doi.org\/10.1111\/bcp.14972","journal-title":"Br J Clin Pharmacol"},{"key":"4962_CR35","doi-asserted-by":"publisher","first-page":"e22884","DOI":"10.1096\/fj.202201340RR","volume":"37","author":"Y Gui","year":"2023","unstructured":"Gui Y, Palanza Z, Fu H et al (2023) Acute kidney injury in diabetes mellitus: epidemiology, diagnostic, and therapeutic concepts. FASEB J 37:e22884. https:\/\/doi.org\/10.1096\/fj.202201340RR","journal-title":"FASEB J"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04962-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04962-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04962-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:21:39Z","timestamp":1790266899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04962-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4962"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04962-1","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"112"}}